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Background: With expanding pediatric antiretroviral therapy
(ART) access, children will begin to experience treatment failure
and require second-line therapy. We evaluated the probability
and determinants of virologic failure and switching in children in
South Africa.
Methods: Pooled analysis of routine individual data from children
who initiated ART in 7 South African treatment programs with
6-monthly viral load and CD4 monitoring produced Kaplan-Meier
estimates of probability of virologic failure (2 consecutive unsup-
pressed viral loads with the second being .1000 copies/mL, after
$24 weeks of therapy) and switch to second-line. Cox-proportional
hazards models stratiﬁed by program were used to determine
predictors of these outcomes.
Results: The 3-year probability of virologic failure among 5485
children was 19.3% (95% conﬁdence interval: 17.6 to 21.1). Use of
nevirapine or ritonavir alone in the initial regimen (compared with
efavirenz) and exposure to prevention of mother to child transmission
regimens were independently associated with failure [adjusted hazard
ratios (95% conﬁdence interval): 1.77 (1.11 to 2.83), 2.39 (1.57 to
3.64) and 1.40 (1.02 to 1.92), respectively]. Among 252 children
with $1 year follow-up after failure, 38% were switched to second-
line. Median (interquartile range) months between failure and switch
was 5.7 (2.9–11.0).
Conclusions: Triple ART based on nevirapine or ritonavir as
a single protease inhibitor seems to be associated with a higher risk of
virologic failure. A low proportion of virologically failing children
were switched.
Key Words: antiretroviral therapy, children, resource-limited setting,
second-line therapy, virologic failure
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INTRODUCTION
With expanding access to antiretroviral therapy (ART)
for HIV-infected children, increasing numbers are likely to
experience treatment failure and require second-line regimens.
Before 2010, WHO pediatric guidelines did not deﬁne
virologic failure (VF) and viral load monitoring remains
unavailable in most resource-limited settings.
1,2 In contrast,
industrialized country guidelines stipulate strict viral load
criteria for switching at thresholds as low as 2 consecutive
measurements .400 copies per milliliter.
3,4
Due to poor access to viral load monitoring in resource-
limited settings, there is limited published data on VF in
children.
1 Existing studies are limited by cohort size, exclusive
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based regimens and/or failure deﬁnitions based on a single
elevated viral load measurement.
5–9 Poor access to and lack of
experience with second-line therapy, and national policies that
may restrict second-line use, have resulted in low numbers and
proportions of children being switched even in larger
cohorts.
5,6,10–14 Predictors of which children are switched in
resource-limited settings have therefore not been examined.
The International epidemiologic Databases to Evaluate
AIDS(IeDEA) SouthernAfrica collaboration includes 7South
African pediatric ART programs with data on more than 6000
children who had initiated treatment before 2008.
15,16 Regular
viral load monitoring (at least 6-monthly) is part of routine
ART care in South Africa.
17 However, until 2010, national
pediatric treatment guidelines did not provide clear direction
on management of VF.
17 We aimed to examine the probability
of VF and its associations, and, in children with VF, to
determine the probability of switching to second-line and
identify factors that predicted which children were switched.
METHODS
Study Design, Setting and Population
Data for this multicenter analysis were collected
prospectively at sites. Each site has institutional ethical
approval for contribution of data to IeDEA analyses and
transferred data anonymously to the IeDEA data center
between May 2007 and February 2008. The analysis included
treatment-naive children (,16 years) initiating ARTwith $3
antiretroviral drugs between June 1999 and February 2008.
Treatment Regimens
All treatment sites are part of the South African national
treatment program that commenced in April 2004 with the
following ﬁrst-line regimen guidelines: stavudine (d4T),
lamivudine (3TC), and either efavirenz (EFV) or if ,3
years/,10kg, a protease inhibitor (PI).
17 For most children,
this was lopinavir/ritonavir (LPV/r), however, ritonavir alone
(RTV) was recommended for children with tuberculosis or ,6
months old.
17 The latter 2 recommendations changed during
2007; LPV/r with additional RTV boosting was introduced for
children with tuberculosis, and LPV/r dosing recommenda-
tions became available for children ,6 months old.
18,19 Some
cohorts introduced these practices before 2007, and also used
more varied regimens before commencement of the national
program, including NNRTI-based regimens in children
,3 years old, RTV alone as the ‘‘third drug’’ in children of
all ages, and zidovudine (ZDV) instead of d4T. National
guidelines were otherwise adhered to in all provinces and
permitted restricted individual drug substitution for intoler-
ance or nonavailability of the recommended drug in suitable
formulation.
17
National guidelines second-line regimens were ZDV +
didanosine with either LPV/r (EFV-based ﬁrst line), or an
NNRTI (PI-based ﬁrst line).
17 The NNRTI was nevirapine
(NVP) for children ,3 years old at switch, and EFV for
older children.
17
Decisions to switch could be made by the program
clinician without formal Department of Health approval.
Second-line regimens were accessible at all sites.
National guidelines advised single dose NVP (sdNVP)
for mother and infant for prevention of mother to child
transmission (PMTCT), with triple ART for pregnant women
with WHO stage 4 disease or CD4 #200 cells per
microliter.
20,21 However, in the Western Cape province,
PMTCT programs began before national roll-out, with
a variety of regimens being used including sdNVP or ZDV
from 34 weeks 6 sdNVP. Similarly, after national implemen-
tation of the sdNVP regimen, the Western Cape province and
McCord Hospital used more effective PMTCT regimens
(Table 1).
22
Key Variables
Sociodemographic and clinical data at ART start
included age, gender, clinical stage [stage 3 (2002 3-stage
WHO classiﬁcation) and stages 3/4 (2005 4-stage WHO
classiﬁcation) were combined],
23,24 exposure to PMTCT
regimens and starting regimen. Weight, viral load, CD4
absolute count and percent were available at ART start and
6-monthly thereafter. Access to viral load and CD4 measure-
ment was similar across sites. Viral load measurements were
performed using Amplicor 1.5 (Roche Diagnostics, Basel,
Switzerland) or NucliSens EasyQ assays (bioMerieux,
Durham, NC), which have good comparability.
25 Severe
immune suppression was deﬁned according to WHO guide-
lines.
2 ‘‘Baseline’’ measurements were those taken closest to
ART initiation and within 6 months (CD4 and viral load) or 2
weeks (weight) prior, to 1 week after commencing ART. Sex-
adjusted weight-for-age z scores (WAZ) were calculated using
WHO 2007 reference values for children #10 years of age.
26
Outcomes
VF was deﬁned as 2 consecutive (#12 months apart)
viral load measurements $400 copies per milliliter with the
second being .1000 copies per milliliter, and both taken after
24 weeks on ART, and not during a treatment interruption.
Sensitivity analyses used different thresholds (400, 5000 and
10,000 copies/mL) to deﬁne VF. Children were considered to
have switched to second-line if any of the following occurred
,1 year after a viral load measurement .400 copies per
milliliter: (1) commencement of $2 new drugs including
a class switch from PI to NNRTI or vice versa; (2) class switch
from NNRTI to PI or vice versa only, with reason documented
as treatment failure; or (3) change of both NRTIs and change
from RTV to LPV/r with reason documented as treatment
failure. Immunologic failure was deﬁned according to South
African guidelines criteria for switching as either CD4%
below baseline value after 24 weeks of therapy or CD4%
,50% of peak value during preceding treatment.
Analysis
Continuous and categorical variables were summarized
using medians and interquartile ranges (IQR) and proportions,
respectively. Kaplan-Meier probabilities of virologic and
immunologic failure and switch were estimated. Predictors
of failure and switch were determined using Cox-proportional
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heterogeneity. Only children with $6 months of follow-up
after failure were included in the switch model. The following
variables were included a priori in multivariable models: age,
gender, and immune suppression at ART initiation (failure
model); age, gender and treatment duration at time of failure
(switch model). Thereafter, multivariable models retained
variables with adjusted P values ,0.1. In comparison to
known lack of PMTCT exposure, missing PMTCT exposure
information had no effect on failure, so these categories were
combined. Separate failure models were generated including
and excluding WAZ and stage, as missing data for these
variables and exclusion of children .10 years old due to lack
of WHO WAZ reference values substantially reduced the
number of children that could be included in the model. The
proportional hazards assumption was met for all models.
Statistical analyses were performed using Stata version 10
(STATA Corporation, College Station, TX).
RESULTS
Data from all South African IeDEA sites providing
pediatric ART were included (Table 1). This comprised 6266
children of whom 781 (12%) were excluded for the following
reasons: missing or inconsistent baseline data (n = 85), non-
naı ¨ve (n = 39), mono/dual therapy (n = 64) and starting
regimen not recorded (n = 593). The ﬁnal dataset comprised
5485 children (49% female) with median (IQR) follow-up of
16 (6–29) months. During follow-up, 344 (6%) children died,
411 (7%) were lost to follow-up and 885 (16%) were
transferred out after median durations of 1.5, 5.8, and 12.9
months, respectively. There were 13,877 viral load and 12,749
CD4 percent measurements during follow-up with median
(IQR) intervals between measurements of 168 (104–190) and
168 (126–197) days, respectively.
Most children were severely ill at ART start (Table 2).
The median (IQR) age of children commencing ART was 42
(15–82) months. The NRTI backbone was d4T/3TC for 89%
of children. The most common ‘‘third’’drugswere EFV (55%),
LPV/r (33%), RTV alone (7%), and NVP (5%).
Virologic Failure
The estimated probability of failure (second elevated
value $ 1,000 copies/mL) by 36 months was 19.3% [95%
conﬁdence interval (CI): 17.6 to 21.1, Fig. 1]. Of the 523
children with VF, 311 (59%) had never been virologically
suppressed. Among these children whose viral load was never
,400 copies per milliliter, 217 had both baseline and
$1 subsequent viral load measurement performed between
6 and 15 months on ART, and 121 (55%) showed a virologic
response to therapy ($1l o g 10 reduction from baseline viral
load during the ﬁrst year on ART). Using different thresholds
for the second unsuppressed viral load, the 36-month
estimated probability of failure ranged from 14.6%
(95% CI: 13.1 to 16.3) (cut-off = 10,000 copies/mL) to
21.1% (95% CI: 19.3 to 23.0) (cut-off = 400 copies/mL)
(Fig. 1). By 1 year and 3 years on ART, the estimated
probabilities of a singleviral load measurement .1,000 copies
TABLE 1. Characteristics of Sites Providing ART for Children
Cohort Name
and Location
Main Level of
Care Provided
Type of Clinic
and Payment
Target
Population
Most Likely
PMTCT Intervention*
First Year of
Pediatric ART
Provision
Number of
Children
on ART
Harriet Shezi, Chris Hani
Baragwanath Hospital,
Soweto
All levels Public and research,
free ART
Children only sdNVP to mother
and infant
2001 1,865
Rahima Moosa Mother and
Child Hospital,
Johannesburg
All levels Public, free ART Children and
pregnant women
sdNVP to mother
and infant
1999 938
Red Cross Children’s
Hospital,
Cape Town
Tertiary Public and research,
free ART
Children only ZDV from 34 weeks
gestation + sdNVP to
mother and infant
2001 828
Tygerberg Hospital,
Cape Town
Tertiary Public, free ART Adults and children,
separate clinics
ZDV from 34 weeks
gestation + sdNVP to
mother and infant
2000 591
Khayelitsha Community
Health Centre,
Cape Town
Primary Public, free ART Adults and children,
separate clinics
ZDV from 34 weeks
gestation + sdNVP to
mother and infant
2001 650
Gugulethu Community
Health Centre,
Cape Town
Primary Public and research,
free ART
Adults and children,
separate clinics
ZDV from 34 weeks
gestation + sdNVP to
mother and infant
2001 209
McCord Hospital, Durban Secondary Government subsidized
not for proﬁt hospital,
small copayment
Adults and children,
combined clinics
sdNVP to mother and
infant
2003 404
Total — — — — — 5485
*This is the PMTCTintervention available through the public health system within the province in which each site is located. It is not necessarily the intervention that each individual
child attending that facility received, as individual program PMTCT regimens varied and mothers may have accessed antenatal care in other provinces/programs.
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(95% CI: 30.2 to 34.1), respectively. By 3 years, 384 children
had immunologic failure with an estimated cumulative
probability of 12.6% (95% CI: 11.3 to 13.0). The probability
of immunologic failure was lower than that for all deﬁnitions
of VF, except in the early months as the immunologic failure
deﬁnition did not require conﬁrmation.
In the multivariable model of associations with VF, viral
load .1 million copies per milliliter at ART initiation was the
only disease characteristic that predicted failure (Table 3).
After adjustment for gender, age, baseline viral load, and
immune suppression, failure risk was increased with use of
either NVP [adjusted hazard ratio (aHR): 1.77; 95%CI: 1.11 to
2.83] or RTV alone (aHR: 2.39; 95% CI: 1.57 to 3.64)
compared with EFV in the initial regimen. Known PMTCT
exposure was also associated with failure (aHR: 1.40; 95%
CI: 1.02 to 1.92). Results were very similar using different
thresholds to deﬁne VF. Results were also similar if addi-
tionally adjusted for WHO stage and WAZ, neither of which
remained independently associated with failure. A further
model was developed excluding children with virologic non-
response, and results were similar except for an attenuated
effect of PMTCT. Results of all additional analyses are shown
in (see Table, Supplemental Digital Content 1,
http://links.lww.com/QAI/A146).
Switching to Second-Line
The estimated probability of switching to second-line
by 3 years after ART initiation for all children was 6.2%
(95% CI: 5.2 to 7.5, Fig. 1). Of the 153 children switched,
TABLE 2. Characteristics of Children at ART Initiation, Failure (Second Consecutive Unsuppressed Viral Load . 1,000 Copies/mL),
and Switch
Characteristic
All Children,
n = 5485
Children
With VF, n = 523
Children With
VF Switched to
Second-Line, n = 145*
Female 2674 (49%) 235 (45%) 51 (35%)
Median (IQR) age (mo)
At ART start 42 (15–82) 37 (13–86) 60 (16–94)
At failure NA 51 (26–103) 74 (29–108)
,12 months of age at ART start 1158 (21%) 123 (23%) 26 (18%)
Severe immune suppression
At ART start 3690/4577 (81%) 384/447 (86%) 119/128 (93%)
At failure NA 184/493 (37%) 57/138 (41%)
Median (IQR) CD4 percent
At ART start, n 12 (7–17) 10 (5–15), 408 7 (3–12), 118
At failure, n NA 20 (14–26), 464 18 (12–25), 127
WHO stage 3 or 4 at ART start 2887/3832 (75%) 275/374 (74%) 88/116 (76%)
Viral load . 1 million copies/mL
At ART start 777/3745 (21%) 110/388 (28%) 29/111 (26%)
At failure NA 13/524 (2%) 4/145 (3%)
Median (IQR) log viral load
At ART start, n 5.3 (4.7–5.9) 5.6 (5.0–6.1), 388 5.6 (5.0–6.1), 111
At failure; n NA 4.2 (3.7–4.9), 524 4.4 (3.9–5.1), 145
Weight-for-age z score ,2 2
At ART start 1759/3646 (48%) 170/329 (52%) 46/89 (52%)
At failure NA 73/385 (19%) 22/103 (21%)
Median (IQR) weight-for-age z score
At ART start, n 21.93 (23.36 to 20.96), 3646 22.08 (23.43 to 21.07), 329 22.14 (23.31 to 20.96), 89
At failure, n NA 20.87 (21.74 to 20.12), 385 20.79 (21.74 to 20.13), 103
PMTCT exposure
Exposed 556 (10%) 67 (13%) 14 (10%)
Known unexposed 1644 (30%) 176 (34%) 61 (42%)
Exposure status unknown 3285 (60%) 280 (53%) 70 (48%)
First-line regimen
d4T and 3TC based 4857 (89%) 420 (80%) 103 (71%)
Nevirapine as third drug 254 (5%) 45 (9%) 20 (14%)
Efavirenz as third drug 3030 (55%) 251 (48%) 88 (61%)
LPV/r as third drug 1819 (33%) 140 (27%) 10 (7%)
Ritonavir alone as third drug 382 (7%) 88 (17%) 27 (19%)
*Eight children were switched to second-line who did not meet criteria for VF but had viral load .400 copies per milliliter preceding switch. These children are excluded from this
column.
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unsuppressed viral load measurement (n = 7), or consecutive
measurements were both before 24 weeks on ART (n = 1).
Of 252 children with $1 year of follow-up after failure,
38% (95% CI: 32% to 45%) were switched. The median (IQR)
time to switch from failure was 5.7 (2.9–11.0) months and
from ﬁrst unsuppressed viral load was 9.5 (5.5–14.6) months.
The median (IQR) interval between consecutive unsuppressed
viral load measurements was 3.2 (2.5–5.4) months.
Most second-line regimens included didanosine as one
of the NRTIs (108 of 153; 71%). Other NRTIs included ZDV
(66%), 3TC (25%); d4T (21%); abacavir (13%), and tenofovir
(1%). The ‘‘third drug’’ in the regimen was LPV/r for 74%
of children.
After adjustment for age at ART initiation, gender and
treatment duration, children with more severe or progressive
disease from the time of failure (higher viral load, CD4% ,25
at switch, CD4% decline .1 percentage point per month
between switch date and preceding visit) were more likely
to be switched, while taking a PI-based initial regimen
was negatively associated with switch (aHR: 0.40; 95%
CI: 0.17 to 0.91) (Table 4). Failure to initially attain viral load
,400 copies per milliliter after starting ART was not
associated with switch in univariable or multivariable analysis.
(aHR: 1.02; 95% CI: 0.52 to 1.99).
DISCUSSION
Main Findings
This study reports in detail on conﬁrmed VF and
switching in children on ART in a large African multicenter
FIGURE 1. Kaplan-Meier probability of virologic failure using
different viral load values (measured in copies/mL) to deﬁne
failure, and immunologic failure and switch. Solid lines indicate
VF deﬁned as 2 consecutive unsuppressed viral loads with the
second viral load being above the threshold value indicated;
dashed line indicates immunologic failure; dash-dot line
indicates switch to second-line. Note: The numbers in
parentheses in the risk table refer to VF events deﬁned as 2
consecutive viral load measurements .400 copies per milliliter
with second viral load .1,000 copies per milliliter, and this is
used as the deﬁnition of failure in analyses.
TABLE 3. Univariable and Multivariable Associations With Virologic Failure in All Children Commenced on ART (Cox-proportional
Hazards Model Stratified by Site)
Failure Deﬁnition
2 Consecutive Unsuppressed
Viral Loads With the Second Being .1,000 Copies/mL
Characteristic at
ART Initiation
Unadjusted HR
(95% CI) n = 5485 P
Adjusted HR
(95% CI), n = 3605 P
Age
$2 yrs 1 ,0.001* 1 0.934*
1–2 yrs 1.37 (1.07 to 1.75) 1.02 (0.71 to 1.48)
,1 year 1.83 (1.47 to 2.28) 1.07 (0.74 to 1.56)
Female gender 0.88 (0.74 to 1.05) 0.16 0.92 (0.75 to 1.13) 0.442
Viral load . 1 million copies/mL 2.05 (1.63 to 2.58) ,0.001 1.67 (1.28 to 2.16) ,0.001
Severe immune suppression 1.48 (1.13 to 1.95) 0.004 1.25 (0.94 to 1.68) 0.131
WHO stage 3 or 4 (vs. 1 or 2)† 1.35 (1.06 to 1.73) 0.016 — —
Weight-for-age z score ,2 3† 1.34 (1.06 to 1.69) 0.014 — —
Third drug in regimen
Efavirenz 1 — 1 —
Nevirapine 1.96 (1.37 to 2.80) ,0.001 1.77 (1.11 to 2.83) 0.016
Lopinavir/ RTV 1.36 (1.10 to 1.67) 0.004 1.07 (0.76 to 1.51) 0.701
Ritonavir alone 3.06 (2.31 to 4.04) ,0.001 2.39 (1.57 to 3.64) ,0.001
PMTCT exposure
Unexposed/unknown 1 — 1 —
Exposed 1.64 (1.25 to 2.14) ,0.001 1.40 (1.02 to 1.92) 0.039
Year of ART initiation‡
.2005 1 — — —
#2005 0.83 (0.66 to 1.04) 0.1 — —
*The P value was derived from Wald’s test.
†Not included in multivariable model as missing information would have limited overall number of children that could be included.
‡Not included in multivariable model as P . 0.1 after adjustment for other variables in the model.
HR, hazard ratio.
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in 5 children had met the analysis deﬁnition of conﬁrmed
VF by 3 years on ART. Baseline viral load .1 million copies
per milliliter, use of either NVP, or RTV as a sole PI, and
PMTCT exposure independently predicted failure. Less than
half of children with $1 year of follow-up after failure were
switched, with a median interval between failure and switch of
5.7 months. Across all sites, current poor immunologic and
virologic status together with being on an NNRTI-based
regimen favored switch.
Time to VF
Previous studies from Thailand and Uganda with all
children on NNRTI-based regimens and failure deﬁned using
a single viral load measurement, reported similar proportions
of children with VF at 12 months on ART as we report at
36 months using conﬁrmed measurements.
5,6 Similarly, a
recent cohort study found the frequency of consecutive viral
load measurements .400 copies per milliliter among 116
children with follow-up $6 months to be 17%.
8 Nevertheless,
the cumulative probability of a single elevated viral load
measurement after 1 year on ARTin our study (16%) is similar
to the Thai and Ugandan studies. In contrast, prevalence of
a singleviral load measurement .400 copies per milliliter was
32% at a Tanzanian pediatric clinic, however, 12% of those
with VF were on second-line.
9 Notwithstanding, our study
differs from these with use of PI-based ﬁrst-line therapy and
possible differences in PMTCT exposure and adherence.
For those on NNRTI-based regimens, the conﬁrmation
of VF following adherence optimization, as reported in this
study, is likely to identify patients who are truly failing with
resistance to $1 drug in the regimen. For example, an adult
study from South Africa showed that 86% of patients with
conﬁrmed viral load .1,000 copies per milliliter had therapy-
limiting NNRTI mutations.
27 Among children with VF in the
Thai study, 89% and 97% had major NRTI and NNRTI
resistance mutations, respectively. We had no access to resis-
tance testing for children failing therapy, and the prevalence of
resistance among children on PI-based regimens with con-
ﬁrmed VF in our context remains unknown.
Comparisons with rich countries are difﬁcult due to
differences in age at ART commencement, previous mono-
therapy or dual therapy, follow-up duration, and ﬁrst-line
regimens. The United Kingdom Collaborative HIV Pediatric
Study reported 32% of 595 children having VF after a median
follow-up of 3 years, whereas a Dutch cohort of 39 children
on nelﬁnavir-based ART reported 74% VF-free survival after
48 weeks.
28,29
First-Line Regimen Choice
The association between NVP-containing regimens and
VF concurs with ﬁndings from previous pediatric and adult
studies.
5,6,30,31 It has been suggested that NVP may be
underdosed in children taking split adult ﬁxed-dose combi-
nation tablets, however, in South Africa, NVP is administered
to children as a single drug in syrup/tablet form.
5,6 Children
may harbor resistance from unrecorded exposure to sdNVP,
and subsequent NVP-based ARTwould be expected to result
in poor virologic outcomes.
32,33 Although the majority of
sdNVP-exposed children in this cohort would have com-
menced PI-based regimens, it is likely that some initiated
NNRTI-based regimens due to site variation in regimen use
TABLE 4. Univariable and Multivariable Associations With Switch to Second-Line Therapy in Children With at Least 6 Months
Follow-Up After a Second Consecutive Unsuppressed Viral Load, With the Second Viral Load Being .1,000 Copies Per Milliliter
(Cox-Proportional Hazards Model Stratified by Site)
Characteristic
Unadjusted HR
(95% CI) n = 367 P
Adjusted HR
(95% CI) n = 229 P
Age in years at ART initiation (per 1 year increase in age) 1.11 (1.05 to 1.16) ,0.001 1.03 (0.87 to 1.23) 0.698
Female gender 0.64 (0.44 to 0.92) 0.017 0.72 (0.42 to 1.25) 0.244
Years on treatment at time of failure (per 1 year duration on treatment) 1.38 (1.04 to 1.84) 0.025 1.37 (0.82 to 2.29) 0.229
Log10 viral load at failure (per 1 log increase) 1.43 (1.15 to 1.78) 0.002 1.55 (1.11 to 2.16) 0.01
Current* immunologic failure† 1.08 (0.67 to 1.75) 0.75 — —
Current* CD4% ,25 2.45 (1.56 to 3.84) ,0.001 1.94 (1.07 to 3.52) 0.029
Current CD4% decline . 1 unit/month‡ 4.37 (2.14 to 8.92) ,0.001 6.44 (2.15 to 19.25) 0.001
Current* weight-for-age z score (per 1 unit increase in z score) 0.94 (0.78 to 1.13) 0.521 1.14 (0.90 to 1.43) 0.281
Current weight-for-age z score decline . 0.1 units/month‡ 1.62 (0.64 to 4.11) 0.313 2.10 (0.58 to 7.58) 0.257
Viral load decline , 1l o g 10 since ART start† 0.88 (0.55 to 1.41) 0.596 — —
PI-containing regimen 0.39 (0.25 to 0.60) ,0.001 0.40 (0.17 to 0.91) 0.03
Year of ART initiation†
.2005 1 — — —
#2005 1.10 (0.52 to 2.32) 0.803 — —
Reasons for children having less than 6 months follow-up after failure (n = 156), were death (n = 5; 3%), loss to follow-up (n = 15; 10%), transfer out (n = 13; 8%) and failure
occurring less than 6 months before database closure (n = 123; 79%).
HR, hazard ratio.
*Measurement taken at time of switch.
†Not include in multivariable model.
‡Difference between measurement taken at time of switch and preceding visit.
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ported by both the ﬁnding of an association between PMTCT
exposure and subsequent failure, despite PMTCT under-
ascertainment, and attenuation of this effect when those
without virologic response to ART were excluded. This
attenuation is expected as children with NVP resistance would
most likely be virologic nonresponders.
Despite our inability to adjust for potential confounding
by concomitant tuberculosis and other confounding by
indication, our ﬁndings suggest that RTV as the sole PI is
indeed associated with failure. RTV is unpleasant tasting,
associated with poor adherence, and results in a greater
accumulation of major PI resistance mutations in comparison
with LPV/r.
34,35 However, as RTV use would have been more
common in children with tuberculosis, we cannot exclude that
worse outcomes may havebeen due to tuberculosis itself or the
increased medication burden of ART combined with
antituberculous therapy.
Switching to Second-Line
This study reﬂects clinical practice in a setting with viral
load monitoring but no supporting national or WHO guide-
lines regarding management of children with VF. This is
reﬂected in the low proportion of children switched after
failure, and the delay between VFand switch. Heterogeneity in
switching practice was also seen in the Collaborative HIV
Pediatric Study with nearly half of children with VF being
switched before the date of ﬁrst viral load .1000 copies per
milliliter but an equal proportion on ﬁrst line $6 months
thereafter.
28 In our study, service factors may contribute to
the delay;clinical appointments areoften 3-monthly withresults
only available for decision-making at subsequent appointments.
Nevertheless, less than half of children with conﬁrmed
VF for $1 year were switched, and those who were switched
were on a failing regimen for a median of 10 months after the
ﬁrst elevated viral load measurement. In this study, factors
other than VF were associated with being switched, including
initial regimen, disease severity and progressive immunolog-
ical decline.
Reluctance to switch a young child failing therapy
without thorough assessment of adherence is reasonable in the
context of access only to unpleasant second-line regimens,
with no third-line/salvage therapy. In this respect, reduced
switching of children on PI-based regimens is consistent with
knowledge that viral escape is more likely due to poor adher-
ence than resistance.
34 Nevertheless, poor access to a wider
range of second-line drugs, particularly for children failing
ﬁrst-line PI-based regimens after sdNVP exposure, may result
in an understandable reluctance to switch children to a drug to
which their virus may be resistant.
If the intention of treatment guidelines is to avoid pro-
longed viremia, this study suggests the need for more intensive
monitoring and adherence interventions soon after a single
elevated viral load. The PENPACT1 trial recently reported
similar outcomes overall for children switched at viral load
measurements of 1000 or 30,000 copies per milliliter, however,
highlighted the importance of adherence interventions after
initial elevated viral load measures.
36,37 In addition, children on
NNRTI-based therapy switched at 30,000 copies per milliliter
accumulated more NRTI-resistant mutations compared with
those switched at 1000 copies per milliliter, suggesting that
switching guidelines should be tailored according to regi-
men.
36,37 In large programs, viral load monitoring could
additionally be used to manage patient load by stratifying
risk. More clinical and adherence input could be given to
unsuppressed patients although those with sustained virologic
suppression could be managed less intensively.
7,38
Strengths and Limitations
This is a large combined cohort of children across many
sites providing different levels of care. In addition, viral load
measurements were available for .75% of children in care at
each 6-monthly duration, and it was possible to use as an
outcome conﬁrmed VF rather than a single measure. The large
number of infants and inclusion of a PI in ﬁrst line enabled us
to examine the effect on virologic outcome of RTVas the sole
PI and LPV/r in comparison to NVP or EFVas components of
ﬁrst-line regimens.
The size of the cohort resulted in a relatively large
absolute number offailures and switches, permitting investiga-
tion of switching practice.
Despite the study size and the general application of the
public health approach to ART provision, the study cohorts,
being relatively well resourced and urban, may not be repre-
sentative of all sites across the region or even South Africa.
Data was collected in the context of routine care in busy
clinics. There is limited data on key possible predictors of VF
such as tuberculosis coinfection, adherence and PMTCT, and
on clinical events. Missing data on other variables limited the
range of variables and number of children that could be
included in multivariable models. Tuberculosis coinfection not
only affects ﬁrst-line regimen choice, but may impact on
virologic outcomes directly or through drug–drug interactions
or reduced adherence. We could not explore the extent to
which our observed associations with failure were mediated
through poor adherence, due to limited data. PMTCT expo-
sure data was only recorded for 40% of children. Furthermore,
exact PMTCT regimens were not recorded, so the effect
of different regimens could not be examined. The effect of
severe clinical disease at ART initiation on VF may have
been reduced by combining stage 3 and 4 disease. Due to
lack of detailed clinical event data and confounding by
indication (with sicker children being preferentially switched),
we were unable to determine the clinical consequences of
delayed switching.
CONCLUSIONS
This study demonstrates the probability of VF in
children on ART in South Africa at 3 years to be nearly
20%. The time between failure and switch and low proportion
of children switched to second-line in this and other studies
supports use of clearer deﬁnitions of VF and clinical practice
guidelines for managing children with unsuppressed viral load
tailored to starting regimen. In addition, access to second-line
drugs for PMTCT exposed children failing PI-based ART is
important for better pediatric HIV care in the countries where
the majority of HIV-infected children reside.
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